Comment on Herring et al. Metabolic Effects of an SGLT2 Inhibitor (Dapagliflozin) During a Period of Acute Insulin Withdrawal and Development of Ketoacidosis in People With Type 1 Diabetes. Diabetes Care 2020;43:2128-2136.

Bolli, Geremia B; Porcellati, Francesca; Lucidi, Paola; Fanelli, Carmine G

Bolli, Geremia B; Porcellati, Francesca; Lucidi, Paola; Fanelli, Carmine G.

Afiliación

Bolli GB; Section of Endocrinology and Metabolism, Department of Medicine, University of Perugia Medical School, Perugia, Italy bolli@unipg.it.
Porcellati F; Section of Endocrinology and Metabolism, Department of Medicine, University of Perugia Medical School, Perugia, Italy.
Lucidi P; Section of Endocrinology and Metabolism, Department of Medicine, University of Perugia Medical School, Perugia, Italy.
Fanelli CG; Section of Endocrinology and Metabolism, Department of Medicine, University of Perugia Medical School, Perugia, Italy.

Diabetes Care ; 44(3): e59-e60, 2021 03.

Article en En | MEDLINE | ID: mdl-33608328

Asunto(s)

Diabetes Mellitus Tipo 1; Cetosis; Inhibidores del Cotransportador de Sodio-Glucosa 2; Compuestos de Bencidrilo; Diabetes Mellitus Tipo 1/tratamiento farmacológico; Glucósidos; Humanos; Insulina; Inhibidores del Cotransportador de Sodio-Glucosa 2/efectos adversos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Inhibidores del Cotransportador de Sodio-Glucosa 2 / Cetosis Límite: Humans Idioma: En Revista: Diabetes Care Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google